stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) EPS (diluted)
Rhythm Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$3.11, compared with −$4.34 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$2.89. Over the past ten years it has ranged from −$4.34 (fiscal 2024) to −$1.09 (fiscal 2015); the current reading is higher than 45% of that period. Rhythm Pharmaceuticals, Inc. ranks 370th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.11 | — |
| FY2024 | −$4.34 | — |
| FY2023 | −$3.20 | — |
| FY2022 | −$3.47 | — |
| FY2021 | −$1.40 | — |
| FY2020 | −$3.04 | — |
| FY2019 | −$3.86 | — |
| FY2018 | −$2.39 | — |
| FY2017 | −$2.83 | — |
| FY2016 | −$2.85 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.60 | — |
| Jun 2026 | −$0.73 | — |
| Mar 2026 | −$0.83 | — |
| Dec 2025 | −$0.73 | — |
| 36 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $1.29 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$2.25 |
| RYTM Rhythm Pharmaceuticals, Inc. | −$2.89 |
| AXSM Axsome Therapeutics, Inc. compare | −$3.06 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
| ABVX Abivax SA Sponsored ADR compare | −$6.06 |
| PRAX Praxis Precision Medicines, Inc. compare | −$12.93 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RYTM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement